ARPO Aerpio Pharmaceuticals Inc.

0.46
-0.04  -8%
Previous Close 0.5
Open 0.5
Price To Book 0.41
Market Cap 18,751,658
Shares 40,588,004
Volume 103,128
Short Ratio
Av. Daily Volume 94,683
Stock charts supplied by TradingView

NewsSee all news

  1. Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma

    Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced interim results from its

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b screening underway - May 14, 2019. Data due 1H 2020.
AKB-4924 (GB004)
Ulcerative Colitis
Phase 2 data released March 18, 2019 did not meet primary endpoint.
AKB-9778 - TIME 2B
Non-Proliferative Diabetic Retinopathy
Phase 1b interim data October 10, 2019. Full data due 1Q 2020.
AKB-9778
Primary open-angle glaucoma (POAG)

Latest News

  1. Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma

    Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced interim results from its